enGene Therapeutics Inc. (ENGN) Free cash flow 2022–2025
enGene Therapeutics Inc. (ENGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$100.7MFY2025 · since FY2022: -$17.7M → -$100.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$100.7M | -104.7% |
| FY2024 | -$49.2M | -96.3% |
| FY2023 | -$25.1M | -41.2% |
| FY2022 | -$17.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENGN financial trends
ENGN RevenueENGN Net incomeENGN Net marginENGN Gross profitENGN Gross marginENGN Operating incomeENGN Operating marginENGN Operating cash flowENGN Capital expendituresENGN Return on equityENGN Stock buybacksENGN Dividends paidENGN Total assetsENGN Total liabilitiesENGN Shareholders’ equityENGN overview →